UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 27, 2024
(Exact Name of Registrant Specified in Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant's telephone number, including area code: 215 -619-3200
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02. |
Results of Operations and Financial Condition.
|
On March 27, 2024, STRATA Skin Sciences, Inc. (the “Company”) issued
a press release announcing its results of operations for the fourth fiscal quarter and full year ended December 31, 2023. The full text of such press release
is furnished as Exhibit 99.1 to this report.
The information set forth under this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
| Item 7.01. |
Regulation FD Disclosure.
|
On March 27, 2024, STRATA Skin Sciences, Inc. (the “Company”) issued a press release announcing its results of operations for the
fourth fiscal quarter and full year ended December 31, 2023. The full text of such press release is furnished as Exhibit 99.1 to this report.
The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
| Item 9.01. |
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
The following press release is furnished as an exhibit to this Current Report on Form 8-K pursuant to Item 2.02 and shall not be
deemed to be “filed”:
|
|
99.1 | Press Release dated March 27, 2024 issued by STRATA Skin Sciences, Inc. |
|
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
STRATA SKIN SCIENCES, INC.
|
|||
|
Date: March 27, 2024
|
By:
|
/s/ Christopher Lesovitz
|
|
|
Christopher Lesovitz
|
|||
|
Chief Financial Officer
|
|||
Exhibit 99.1
STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings
Company to host conference call and webcast today, March 27, 2024,
at 4:30 PM ET
HORSHAM, Pa., Mar. 27, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or “the
Company”), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the
fourth quarter and full-year ended December 31, 2023.
Fourth Quarter and Full-Year 2023 and Recent Business Highlights:
| ● |
Revenue in the fourth quarter of 2023 was $8.7 million
|
| ○ |
Global recurring revenue was $5.6 million
|
| ○ |
Gross domestic recurring billings were $5.3 million
|
| ● |
Revenue for the full-year 2023 was $33.4 million
|
| ○ |
Global recurring revenue was $21.5 million
|
| ○ |
Gross domestic recurring billings were $20.2 million
|
| ● |
Increased domestic installed base to 923 XTRAC® devices at December 31, 2023
|
| ● |
Launched new TheraClear®X Acne Therapy System in January 2023 and implemented the recurring revenue model in December 2023, which targets clinical dermatology insurance reimbursed
procedures - currently 92 devices in operation by year end
|
| ● |
Announced leadership transition, in October 2023, with Dr. Dolev Rafaeli appointed as Vice-Chairman, President and Chief Executive Officer
|
| ● |
Reimplemented strategic revenue model emphasizing recurring revenue through a Direct-to-Consumer (DTC) approach, providing value add services to its partner clinics
|
| ● |
Completed sales and marketing department optimization in July 2023 which directly lead to a reduction of sales and marketing expenditures for the year, with full benefits expected to be realized in
2024
|
| ● |
Amended credit facility with MidCap Financial Trust to refinance existing debt and ensure alignment with the Company’s current and future business projections by supporting operational and capital
needs
|
| ● |
Initiated outreach initiative focused on broadening Current Procedural Terminology (“CPT”) code coverage to increase patient access to advanced treatments and enable higher provider reimbursement
rates
|
| ● |
Showcased TheraClear®X and XTRAC® products at Maui Derm 2024, demonstrating the TheraClearX® safety and efficacy in significantly reducing cystic and papular acne
lesions by over 50% within 1-2 weeks
|
“2023 was a pivotal year for STRATA, marked by strategic growth, product innovation, and market expansion,” stated Dr. Dolev Rafaeli, Vice-Chairman, President and CEO of
STRATA. He continued, “We entered the large acne treatment market with the successful launch of our TheraClearX® device, expanded our terms with our credit facility to further influence growth, and re-invigorated the DTC recurring
revenue model that was in place during my previous tenure as CEO, making it more robust than before. As we continue to ramp up this model, we are focused on executing our strategic priorities - driving utilization and placements of our XTRAC®
and TheraClearX® systems, pursuing opportunities in new geographies, and leveraging our patient-focused marketing to increase awareness and adoption of our treatments. I am excited to lead STRATA in this next chapter as we work to
improve operating results and deliver value to our shareholders.”
Fourth Quarter 2023 Financial Results
Revenues for the fourth quarter of 2023 were $8.7 million, as compared to revenues of $10.6 million for the fourth quarter of 2022. Global recurring revenues for the
fourth quarter of 2023 were $5.6 million, as compared to global recurring revenues of $6.5 million for the fourth quarter of 2022. Equipment revenues were $3.1 million for the fourth quarter of 2023, as compared to $4.1 million for the fourth
quarter of 2022.
Gross profit for the fourth quarter of 2023 was $4.8 million, or 55% of revenues, as compared to $6.8 million, or 65% of revenues, for the fourth quarter of 2022.
Selling and marketing costs for the fourth quarter of 2023 were $2.8 million, as compared to $3.8 million for the fourth quarter of 2022. General and administrative costs
for the fourth quarter of 2023 were $2.8 million, as compared to $2.5 million for the fourth quarter of 2022.
Impairment expense for the fourth quarter of 2023 was $2.3 million, related to goodwill impairment in the dermatology recurring procedures segment. There was no
impairment expense in the fourth quarter of 2022.
Other expenses for the fourth quarter of 2023 were $0.4 million, compared to $0.2 million for the fourth quarter of 2022.
Net loss for the fourth quarter of 2023 was $3.8 million, which included the realization of the goodwill impairment of $2.3 million. This resulted in a net loss of $0.11
per basic and diluted common share. Compared to the fourth quarter of 2022, net loss was $0.2 million or a net loss of $0.005 per basic and diluted common share.
Full Year 2023 Financial Results
Revenues for the full year 2023 were $33.4 million, as compared to revenues of $36.2 million for the full year 2022. Global recurring revenues for the full year 2023 were
$21.5 million, as compared to global recurring revenues of $23.0 million for the full year 2022. Equipment revenues were $11.8 million for the full year 2023, as compared to $13.1 million for the full year 2022.
Gross profit for the full year 2023 was $18.5 million, or 55.3% of revenues, as compared to $21.8 million, or 60.2% of revenues, for the full year 2022.
Selling and marketing costs for the full year 2023 were $13.0 million, as compared to $15.3 million for the full year 2022. General and administrative costs for the full
year 2023 were $10.5 million, as compared to $10.1 million for the full year 2022.
Impairment expense for the full year 2023 was $2.3 million, related to goodwill impairment in the dermatology recurring procedures segment. There was no impairment
expense in 2022.
Other expenses for the full year 2023 were $2.3 million compared to $0.8 million for the full year 2022.
Net loss for the full year 2023 was $10.8 million, which included the realization of the goodwill impairment of $2.3 million. This resulted in a net loss of $0.31 per
basic and diluted common share. Compared to last year, net loss was $5.6 million or a net loss of $0.16 per basic and diluted common share.
Cash, cash equivalents and restricted cash at December 31, 2023, were $8.1 million.
Webcast and Conference Call Information
STRATA management will host a conference call today, beginning at 4:30 PM ET. The conference call will be concurrently webcast. The link to the webcast is available here:
4Q23 & Full Year Earnings Webcast and will be archived for future reference. To listen to the conference call, please dial 877-269-7756 (US/Canada), 201-689-7817 (International), and
use the conference ID number 13736453.
Non-GAAP Financial Measures
We have determined to supplement our consolidated financial statements, prepared in accordance with accounting principles generally accepted in the United States of
America (“U.S. GAAP”), presented elsewhere within this report, with certain non-GAAP measures of financial performance. These non-GAAP measures include non-GAAP gross profit, which excludes the non-cash expense of amortization of acquired
intangible assets classified as cost of revenues, and non-GAAP adjusted EBITDA, “Earnings Before Interest, Taxes, Depreciation, and Amortization.”
These non-GAAP disclosures have limitations as an analytical tool, should not be viewed as a substitute for Gross Profit or Net Earnings (Loss) determined in accordance
with U.S. GAAP, should not be considered in isolation or as a substitute for analysis of our results as reported under U.S. GAAP, nor are they necessarily comparable to non-GAAP performance measures that may be presented by other companies. We
consider these non-GAAP measures in addition to our results prepared under current accounting standards, but they are not a substitute for, nor superior to, U.S. GAAP measures. These non-GAAP measures are provided to enhance readers’ overall
understanding of our current financial performance and to provide further information for comparative purposes. This supplemental presentation should not be construed as an inference that the Company's future results will be unaffected by similar
adjustments to Gross Profit or Net Earnings (Loss) determined in accordance with U.S. GAAP. Specifically, we believe the non-GAAP measures provide useful information to management and investors by isolating certain expenses, gains and losses that
may not be indicative of our core operating results and business outlook. In addition, we believe non-GAAP measures enhance the comparability of results against prior periods.
Reconciliation to the most directly comparable U.S. GAAP measure of all non-GAAP measures included in this Annual Report is as follows:
|
|
Year Ended December 31,
|
|||||||
|
(in thousands)
|
2023
|
2022
|
||||||
|
Net loss
|
(10,830
|
)
|
$
|
(5,549
|
)
|
|||
|
|
||||||||
|
Adjustments:
|
||||||||
|
Depreciation and amortization
|
5,553
|
5,293
|
||||||
|
Amortization of operating lease right-of-use asset
|
349
|
395
|
||||||
|
Loss on disposal of property and equipment
|
72
|
52
|
||||||
|
Benefit from / (provision for) income taxes
|
(92
|
)
|
63
|
|||||
|
Interest income
|
(231
|
)
|
(89
|
)
|
||||
|
Interest expense
|
1,640
|
926
|
||||||
|
Non-GAAP EBITDA
|
(3,539
|
)
|
1,091
|
|||||
|
Impairment of goodwill
|
2,284
|
—
|
||||||
|
Stock-based compensation
|
1,303
|
1,466
|
||||||
|
Loss on debt extinguishment
|
909
|
—
|
||||||
|
Non-GAAP adjusted EBITDA
|
$
|
957
|
$
|
2,557
|
||||
XTRAC Gross Domestic Recurring Billings
XTRAC gross domestic recurring billings represent the amount invoiced to partner clinics when treatment codes are sold to the physician. It does not include normal GAAP
adjustments, which are deferred revenue from prior quarters recorded as revenue in the current quarter, the deferral of revenue from the current quarter recorded as revenue in future quarters, adjustments for co-pay and other discounts. This
excludes international recurring revenues.
The following is a reconciliation of non-GAAP XTRAC gross domestic billings to domestic recorded revenue for the third quarter of 2023 and 2022 (in thousands):
|
|
Three Months Ended
December 31,
|
YTD
|
||||||||||||||
|
(in thousands)
|
2023
|
2022
|
2023
|
2022
|
||||||||||||
|
Gross domestic recurring billings
|
$
|
4,947
|
$
|
5,768
|
$
|
19,622
|
$
|
22,271
|
||||||||
|
Co-Pay adjustments
|
(87
|
)
|
294
|
(343
|
)
|
(268
|
)
|
|||||||||
|
Other discounts
|
(22
|
)
|
(40
|
)
|
(110
|
)
|
(163
|
)
|
||||||||
|
Deferred revenue from prior quarters
|
1,913
|
2,309
|
2,170
|
1,867
|
||||||||||||
|
Deferral of revenue to future quarters
|
(1,624
|
)
|
(2,170
|
)
|
(1,624
|
)
|
(2,170
|
)
|
||||||||
|
GAAP Recorded domestic revenue
|
$
|
5,127
|
$
|
6,161
|
$
|
19,715
|
$
|
21,537
|
||||||||
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing and marketing innovative products for the in-office treatment of various
dermatologic conditions such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per
treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising
support to help raise awareness and promote the program within the practice.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not
limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell an acne
treatment device and to integrate that device into its product offerings, the Company’s ability to develop, launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing
campaigns, direct to dermatologist marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties
and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions or supply chain interruptions resulting from the
coronavirus and political factors or conditions affecting the Company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such
uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its
website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC
disclosures available at www.sec.gov and www.strataskinsciences.com.
Investor Contact:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
sskn@cg.capital
STRATA Skin Sciences, Inc. and Subsidiary
Consolidated Balance Sheets
(in thousands, except share and per share data)
|
|
December 31,
|
|||||||
|
|
2023
|
2022
|
||||||
|
Assets
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
6,784
|
$
|
5,434
|
||||
|
Restricted cash
|
1,334
|
1,361
|
||||||
|
Accounts receivable, net of allowance for credit losses of $222 and
$382 at December 31, 2023 and 2022, respectively
|
4,440
|
4,471
|
||||||
|
Inventories
|
2,673
|
3,095
|
||||||
|
Prepaid expenses and other current assets
|
312
|
691
|
||||||
|
Total current assets
|
15,543
|
15,052
|
||||||
|
Property and equipment, net
|
11,778
|
9,950
|
||||||
|
Operating lease right-of-use assets
|
626
|
975
|
||||||
|
Intangible assets, net
|
7,319
|
17,394
|
||||||
|
Goodwill
|
6,519
|
8,803
|
||||||
|
Other assets
|
231
|
98
|
||||||
|
Total assets
|
$
|
42,016
|
$
|
52,272
|
||||
|
|
||||||||
|
Liabilities and Stockholders’ Equity
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
3,343
|
$
|
3,425
|
||||
|
Accrued expenses and other current liabilities
|
6,306
|
6,555
|
||||||
|
Deferred revenues
|
2,120
|
2,778
|
||||||
|
Current portion of operating lease liabilities
|
352
|
355
|
||||||
|
Current portion of contingent consideration
|
53
|
313
|
||||||
|
Total current liabilities
|
12,174
|
13,426
|
||||||
|
Long-term debt, net
|
15,044
|
7,476
|
||||||
|
Deferred revenues and other liabilities
|
552
|
314
|
||||||
|
Deferred tax liability
|
186
|
306
|
||||||
|
Operating lease liabilities, net of current portion
|
237
|
610
|
||||||
|
Contingent consideration, net of current portion
|
1,135
|
8,309
|
||||||
|
Total liabilities
|
29,328
|
30,441
|
||||||
|
Commitments and contingencies (Note 11)
|
||||||||
|
Stockholders’ equity:
|
||||||||
|
Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized, no shares issued and outstanding
|
—
|
—
|
||||||
|
Common stock, $0.001 par value; 150,000,000 shares authorized;
35,060,920 and 34,723,046 shares issued and outstanding at December 31,2023 and 2022, respectively
|
35
|
35
|
||||||
|
Additional paid-in capital
|
250,711
|
249,024
|
||||||
|
Accumulated deficit
|
(238,195
|
)
|
(227,228
|
)
|
||||
|
Total stockholders’ equity
|
12,688
|
21,831
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
42,016
|
$
|
52,272
|
||||
STRATA Skin Sciences, Inc. and Subsidiary
Consolidated Statements of Operations
(in thousands, except share and per share data)
|
|
Year Ended December 31,
|
|||||||
|
|
2023
|
2022
|
||||||
|
Revenues, net
|
$
|
33,358
|
$
|
36,161
|
||||
|
Cost of revenues
|
14,897
|
14,393
|
||||||
|
Gross profit
|
18,461
|
21,768
|
||||||
|
Operating expenses:
|
||||||||
|
Engineering and product development
|
1,317
|
1,029
|
||||||
|
Selling and marketing
|
12,956
|
15,301
|
||||||
|
General and administrative
|
10,508
|
10,087
|
||||||
|
Impairment of goodwill
|
2,284
|
—
|
||||||
|
|
27,065
|
26,417
|
||||||
|
Loss from operations
|
(8,604
|
)
|
(4,649
|
)
|
||||
|
Other (expense) income:
|
||||||||
|
Interest expense
|
(1,640
|
)
|
(926
|
)
|
||||
|
Interest income
|
231
|
89
|
||||||
|
Loss on debt extinguishment
|
(909
|
)
|
—
|
|||||
|
|
(2,318
|
)
|
(837
|
)
|
||||
|
Loss before income tax expense
|
(10,922
|
)
|
(5,486
|
)
|
||||
|
Income tax benefit (expense)
|
92
|
(63
|
)
|
|||||
|
Net loss
|
$
|
(10,830
|
)
|
$
|
(5,549
|
)
|
||
|
|
||||||||
|
Net loss per share of common stock, basic and diluted
|
$
|
(0.31
|
)
|
$
|
(0.16
|
)
|
||
|
Weighted average shares of common stock outstanding, basic and diluted
|
34,920,291
|
34,712,246
|
||||||
STRATA Skin Sciences, Inc. and Subsidiary
Consolidated Statements of Cash Flows
(in thousands)
|
|
Year Ended December 31,
|
|||||||
|
|
2023
|
2022
|
||||||
|
Cash flows from operating activities:
|
||||||||
|
Net loss
|
$
|
(10,830
|
)
|
$
|
(5,549
|
)
|
||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
|
Depreciation and amortization
|
5,553
|
5,293
|
||||||
|
Impairment expense
|
2,284
|
—
|
||||||
|
Amortization of operating lease right-of-use assets
|
349
|
395
|
||||||
|
Amortization of deferred financing costs and debt discount
|
140
|
157
|
||||||
|
Change in allowance for credit losses
|
(110
|
)
|
107
|
|||||
|
Stock-based compensation expense
|
1,303
|
1,466
|
||||||
|
Loss on debt extinguishment
|
909
|
—
|
||||||
|
Loss on disposal of property and equipment
|
72
|
52
|
||||||
|
Deferred income taxes
|
(120
|
)
|
40
|
|||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable
|
141
|
(1,145
|
)
|
|||||
|
Inventories
|
689
|
(1,340
|
)
|
|||||
|
Prepaid expenses and other assets
|
246
|
(111
|
)
|
|||||
|
Accounts payable
|
(100
|
)
|
603
|
|||||
|
Accrued expenses and other liabilities
|
(197
|
)
|
229
|
|||||
|
Deferred revenues
|
(472
|
)
|
(644
|
)
|
||||
|
Operating lease liabilities
|
(376
|
)
|
(477
|
)
|
||||
|
Net cash used in operating activities
|
(519
|
)
|
(924
|
)
|
||||
|
Cash flows from investing activities:
|
||||||||
|
Purchase of property and equipment
|
(5,019
|
)
|
(3,736
|
)
|
||||
|
Cash paid in connection with TheraClear asset acquisition
|
—
|
(631
|
)
|
|||||
|
Net cash used in investing activities
|
(5,019
|
)
|
(4,367
|
)
|
||||
|
Cash flows from financing activities:
|
||||||||
|
Proceeds from long-term debt
|
7,000
|
—
|
||||||
|
Payment of deferred financing costs
|
(97
|
)
|
—
|
|||||
|
Payment of contingent consideration
|
(42
|
)
|
(500
|
)
|
||||
|
Net cash provided by (used in) financing activities
|
6,861
|
(500
|
)
|
|||||
|
Net increase (decrease) in cash, cash equivalents and restricted cash
|
1,323
|
(5,791
|
)
|
|||||
|
Cash, cash equivalents and restricted cash at beginning of year
|
6,795
|
12,586
|
||||||
|
Cash, cash equivalents and restricted cash at end of year
|
$
|
8,118
|
$
|
6,795
|
||||
|
|
||||||||
|
Supplemental disclosure of cash flow information:
|
||||||||
|
Cash paid during the year for interest
|
$
|
1,415
|
$
|
744
|
||||
|
Cash paid during the year for income taxes
|
$
|
22
|
$
|
19
|
||||
|
Supplemental schedule of non-cash operating, investing and financing activities:
|
||||||||
|
Modification of common stock warrants
|
$
|
384
|
$
|
—
|
||||
|
Transfer of property and equipment to inventories
|
$
|
267
|
$
|
463
|
||||
|
Change in intangible assets and fair value of contingent consideration
|
$
|
7,374
|
$
|
—
|
||||
|
Accrued exit fee recorded as debt discount
|
$
|
450
|
$
|
—
|
||||
|
Accrued payment of contingent consideration
|
$
|
18
|
$
|
—
|
||||
|
Inventories acquired in connection with TheraClear asset acquisition
|
$
|
—
|
$
|
71
|
||||
|
Intangible assets acquired in connection with TheraClear asset acquisition
|
$
|
—
|
$
|
10,182
|
||||
|
Contingent consideration issued in connection with TheraClear asset
|
$
|
—
|
$
|
9,122
|
||||
|
Common stock issued in connection with TheraClear asset acquisition
|
$
|
—
|
$
|
500
|
||||
|
Change in operating lease right-of-use assets and liabilities due to new and amended leases
|
$
|
—
|
$
|
732
|
||||